Among research news last week, Gilead Sciences released positive new Phase III data on progression fee survival for its Trodelvy plus Keytruda in breast cancer. Roivant company Immunovant last week ...

The European Medicines Agency’s (EMA)) human medicines committee (CHMP) has recommended seven novel medicines for approval at ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Beyonttra (acoramidis), from Germany’s Bayer ...

Chinese biotech LTZ Therapeutics has closed an oversubscribed series A+ financing round, raising $40 million to support its ...

US biotech Equillium’s (Nasdaq EQ) shares fell by 3% to $0.47 after the company announced that the US Food and Drug ...

A new analysis by Charles River Associates, commissioned by European industry group EFPIA, suggests that a proposed reward ...

Precision oncology company Guardant Health has announced a strategic collaboration with Pfizer to support the development and ...

US drugmaker AbbVie was trading nearly 3% higher lunchtime Friday following the presentation of its first-quarter financial ...

Gilead Sciences (Nasdaq: GILD) reported flat revenues for the first quarter of 2025, with total sales reaching $6.7 billion, ...

Swiss-American biotech Granite Bio has exited stealth mode with $100 million in funding and plans to advance two experimental ...

UK-listed medtech Convatec Group (LSE: CTEC) plans to launch its new wound care technology, ConvaNiox (nitric oxide), later ...

California-based biotech Halozyme Therapeutics (Nasdaq: HALO) yesterday revealed it has filed a patent infringement lawsuit ...